Letter from the Editor
Scott M. Lippman .......................................................... 1

Perspectives

Retinoid Chemoprevention Trials: Cyclin D1 in the Crosshairs. Sarah J. Freemantle, Yongli Guo and Ethan Dmitrovsky .......................................................... 3

Rapamycin for Chemoprevention of Upper Aerodigestive Tract Cancers. Phillip A. Dennis ............... 7

Different Perspective

Oral-Specific Chemical Carcinogenesis in Mice: An Exciting Model for Cancer Prevention and Therapy. Kwong-Kwok Wong .................................................. 10

Research Articles


Targeting Mammalian Target of Rapamycin by Rapamycin Prevents Tumor Progression in an Oral-Specific Chemical Carcinogenesis Model. Rakefet Czerninski, Panomwat Amornphimoltham, Vyomesh Patel, Alfredo A. Molinolo and J. Silvio Gutkind .......................................................... 27

A Pilot Study of Sampling Subcutaneous Adipose Tissue to Examine Biomarkers of Cancer Risk. Kristin L. Campbell, Karen W. Makar, Mario Kratz, Karen E. Foster-Schubert, Anne McTiernan and Cornelia M. Ulrich .......................................................... 37

Chemoprevention of Colorectal Neoplasia by Estrogen: Potential Role of Vitamin D Activity. Petr Protiva, Heide S. Cross, Michael E. Hopkins, Enikő Kállay, Giovanna Bises, Eleanor Dreyhaupt, Leonard Augenlicht, Martin Lipkin, Martin Lesser, Elyane Livote and Peter R. Holt .......................................................... 43

Estrogen Receptor-β as a Potential Target for Colon Cancer Prevention: Chemoprevention of Azoxymethane-Induced Colon Carcinogenesis by Raloxifene in F344 Rats. Naveena B. Janakiram, Vernon E. Steele and Chinthalapally V. Rao .......................................................... 52

Inflammation-Associated Serum and Colon Markers as Indicators of Dietary Attenuation of Colon Carcinogenesis in ob/ob Mice. Roycelynn A. Mentor-Marcel, Gerd Bobe, Kathleen G. Barrett, Matthew R. Young, Paul S. Albert, Maurice R. Bennink, Elaine Lanza and Nancy H. Colburn .......................................................... 60

Selenium and Risk of Bladder Cancer: A Population-Based Case-Control Study. Kristin Wallace, Karl T. Kelsey, Alan Schned, J. Steven Morris, Angeline S. Andrew and Margaret R. Karagas .......................................................... 70

Growth Inhibition and Regression of Lung Tumors by Silibinin: Modulation of Angiogenesis by Macrophage-Associated Cytokines and Nuclear Factor-κB and Signal Transducers and Activators of Transcription 3. Alpna Tyagi, Rana P. Singh, Kumaraguruparan Ramasamy, Komal Raina, Elizabeth F. Redente, Lori D. Dwyer-Nield, Richard A. Radcliffe, Alvin M. Malkinson and Rajesh Agarwal .......................................................... 74

Anthocyanins in Black Raspberries Prevent Esophageal Tumors in Rats. Li-Shu Wang, Stephen S. Hecht, Steven G. Carmella, Nanxiong Yu, Bethany Larue, Cassandra Henry, Colleen McIntyre, Claudio Rocha, John F. Lechner and Gary D. Stoner .......................................................... 84
**Letter to the Editor**

The Role of *Helicobacter pylori* in the Spectrum of Barrett’s Carcinogenesis. Matteo Fassan, Massimo Rugge, Paola Parente, Chiara Tieppo, and Giorgio Battaglia ................................................................. 94

**Correction**

Correction: Adiponectin Inhibits Cancer Cell Proliferation ................................................................................................. 95

---

**About the Cover**

The cover image is a photomicrograph (60X magnification) of immunocytochemical staining for estrogen receptor-β (ER-β) expression in cultured human HCT-116 colon cancer cells. Associated with colon carcinogenesis, ER-β expression is a potential target for colorectal cancer prevention and treatment. The receptor’s expression in human colon cancer cells is highly localized in the nuclei (intense brownish, dark staining). Sporadic colorectal cancer models suggest that ER-β expression (protein and RNA) is selectively associated with cells of colorectal tumors but not normal-appearing epithelia. Furthermore, the selective estrogen-receptor modulator raloxifene suppressed human colon cancer cell growth *in vitro* and in chemically induced colon carcinogenesis in rats. These findings support the promise of ER-β as a target for colorectal cancer chemoprevention.

See article by Janakiram *et al.* (beginning on page 52) for more information.